Photopheresis for early skin lymphoma in adults
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) and weigh under 40 kg, with usable veins for an IV
- You have confirmed mycosis fungoides (skin biopsy that matches the diagnosis) and stage IA, IB, or IIA with measurable skin lesions
- You’re not currently on any other investigational (trial) drug or device, and you can follow study rules
- If you’re on certain skin or lymphoma medicines, you can safely stop them for the required “washout” time before starting
- Your disease is not controlled despite at least one standard treatment for early stages (like topical steroids, bexarotene, PUVA/UVB, or methotrexate)
- You can avoid sunbathing/phototherapy/tanning beds during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
This trial tests a low-dose radiation treatment to the skin for early-stage mycosis fungoides, a type of lymphoma that affects the skin. The goal is to see if this treatment can help eliminate the cancer cells.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial tests a spray solution applied to skin lesions caused by mycosis fungoides, a type of cutaneous T cell lymphoma. It aims to see how the spray affects bacteria on the skin and whether it helps the lesions.
This trial tests a gel form of a drug called duvelisib that you apply directly to skin lesions. It is for people with early-stage mycosis fungoides and may help control the patches without needing whole-body treatments.
This early-stage study tests whether a cancer-killing cream (imiquimod) combined with targeted local radiation can shrink and control mycosis fungoides skin lesions. It may help people whose skin lymphoma has not responded to at least one prior standard treatment.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.